TXMD TherapeuticsMD Inc.

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Date	Price Target	Rating	Analyst
3/11/2022	$3.00 → $2.50	Buy	HC Wainwright & Co.
11/12/2021	$4.00 → $3.00	Buy	HC Wainwright & Co.

TherapeuticsMD Inc.

Peers

Recent Analyst Ratings for TherapeuticsMD Inc.

TherapeuticsMD Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

Director Collins Cooper C. bought $7,099 worth of shares (4,094 units at $1.73), increasing direct ownership by 9% to 52,016 units (SEC Form 4)

Director Collins Cooper C. bought $2,039 worth of shares (1,200 units at $1.70), increasing direct ownership by 3% to 47,922 units (SEC Form 4)

TherapeuticsMD Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

TherapeuticsMD Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

Director Collins Cooper C. converted options into 8,500 shares, increasing direct ownership by 16% to 60,516 units (SEC Form 4)

Director Naughton Gail K converted options into 8,500 shares (SEC Form 4)

Director Thompson Tommy G converted options into 8,500 shares, increasing direct ownership by 143% to 14,454 units (SEC Form 4)

Chief Executive Officer Walker Marlan D converted options into 8,281 shares, increasing direct ownership by 13% to 70,846 units (SEC Form 4)

Director Collins Cooper C. bought $7,099 worth of shares (4,094 units at $1.73), increasing direct ownership by 9% to 52,016 units (SEC Form 4)

Director Collins Cooper C. bought $2,039 worth of shares (1,200 units at $1.70), increasing direct ownership by 3% to 47,922 units (SEC Form 4)

Walker Marlan D converted options into 70,000 shares and sold $43,684 worth of shares (19,050 units at $2.29), increasing direct ownership by 439% to 62,565 units (SEC Form 4)

TherapeuticsMD Inc. FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

FDA Approval for BIJUVA issued to THERAPEUTICSMD INC